ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

INDP vs PHAT // EV/EBITDA & P/E VALUATION

Indaptus Therapeutics Inc. (NASDAQ) VS. Phathom Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: INDP 2 — PHAT 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (INDP VS. PHAT) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC INDP PHAT SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 87.10% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield -2.89% — — TIE /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -0.10% — TIE /net-margins <GO>
Revenue Growth (YoY) — 180.00% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 4/9 -2.00 PHAT /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 53.2 36.7 +16.50 INDP /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $474.6M $466.6M $8.0M INDP /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR INDP REV PHAT REV INDP GROSS % PHAT GROSS % INDP FCF PHAT FCF
FY 2025 $55.5M $175.1M — 87.1% -$14.8M -$167.0M
FY 2024 $43.0M $55.3M — 85.6% -$12.3M -$266.9M
FY 2023 $45.9M $682.0K — — -$13.4M -$137.6M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
INDP // BETA —
PHAT // BETA —